Login
Companies $TRDA
$5.12 +$0.12 (2.4%) After hours
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc.

entradatx.com

What Do They Do?

Develops genetic medicines designed to reach targets inside cells, including treatments for Duchenne muscular dystrophy and inherited retinal diseases.

How Do They Make Money?

Substantially all revenue to date has come from Vertex under a collaboration agreement; payments relate to research activities, with potential milestone payments and royalties on future product sales.

FY2025 revenue

Who Are Their Customers?

Vertex is a collaboration partner for the DM1 program; Entrada conducts research activities under the agreement, while Vertex is responsible for global development, manufacturing and commercialization.

Do Revenues Turn Into Profits?

No. It lost $143.8M in FY2025.

Operating income, FY2025
−621% of revenue
▼ Turned to a loss vs FY2024 ($47M, 22%)
Net income, FY2025
−565% of revenue
▼ Turned to a loss vs FY2024 ($65.6M, 31%)
Free cash flow, FY2025
−510% of revenue
▼ −190% (Loss) vs FY2024 (−$44.7M, −21%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −44%
vs $1.6M in Q3 FY2025
Net income
▲ +10% (Loss)
vs −$44.1M in Q3 FY2025

Expanded disease focus The older report described discovery efforts in immunology and metabolic disease alongside neuromuscular and ocular programs. The latest report describes a pipeline spanning neuromuscular and inherited retinal diseases, with an ocular candidate named.

Who Do They Compete With?

Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Avidity Biosciences, Novartis, Wave Life Sciences, Dyne Therapeutics, BioMarin Pharmaceutical, Solid Biosciences, REGENXBIO, AMO Pharma, PepGen, Design Therapeutics, Expansion Therapeutics, Sepul Bio, Nacuity Pharmaceuticals, and Reforgene

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support